References in periodicals archive ?
Xiapex - collagenase clostridium histolyticum - offers an alternative treatment option to surgery for the condition and can be administered by a trained physician.
You can have surgery or radiation, and a treatment is available called collagenase clostridium histolyticum that is injected.
Therapeutic use: Collagenase clostridium histolyticum (7, 8) is indicated for the treatment of Dupuytren's contracture with a palpable cord in adults.
Recommended dosage: Collagenase clostridium histolyticum is dosed at 0.
Adverse reactions: The most common adverse effects associated with the use of collagenase clostridium histolyticum include swelling of the injected hand, contusion, injection site reaction, injection site hemorrhage, and pain in the injection site hand.
Other comments: Collagenase clostridium histolyticum should be administered by a health care provider experienced in injection procedures of the hand and in the treatment of patients with Dupuytren's contracture.
The product, collagenase Clostridium histolyticum, was approved specifically for adults with Dupuytren's contracture with a palpable cord, and will be marketed as Xiaflex by Auxilium Pharmaceuticals Inc.
1 Collagenase clostridium histolyticum is the first injectable treatment to be approved in the EU for the treatment of Dupuytren's contracture.
The EU approval of collagenase clostridium histolyticum is based on results from two pivotal studies, Collagenase Option for Reduction of Dupuytren's (CORD I and CORD II).
Pfizer has the marketing rights to collagenase clostridium histolyticum in Europe, and Auxilium Pharmaceuticals, Inc.
The FDA's Arthritis Advisory Committee voted 12-0 that the treatment, collagenase Clostridium histolyticum, should be approved for treating advanced Dupuytren's, based on the available safety and efficacy data.
Have had an allergic reaction to collagenase clostridium histolyticum or any of the ingredients in XIAFLEX, or to any other collagenase product.